NEW YORK (AP) — Genentech Inc.'s third-quarter profit rose 6.7 percent on rising sales of key cancer drugs, the biotechnology company said Tuesday, matching Wall Street's profit forecasts. The company lowered the top end of its expected outlook for the year as a result of costs for a program it created in response to an unsolicited buyout offer during the quarter from cancer drug partner Roche.
